Precigen (Precigen) Retained Earnings : $-1,964.47 Mil (As of Dec. 2023)

View and export this data going back to 2013. Start your Free Trial

What is Precigen Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Precigen's retained earnings for the quarter that ended in Dec. 2023 was $-1,964.47 Mil.

Precigen's quarterly retained earnings declined from Jun. 2023 ($-1,911.62 Mil) to Sep. 2023 ($-1,931.42 Mil) and declined from Sep. 2023 ($-1,931.42 Mil) to Dec. 2023 ($-1,964.47 Mil).

Precigen's annual retained earnings increased from Dec. 2021 ($-1,915.56 Mil) to Dec. 2022 ($-1,868.57 Mil) but then declined from Dec. 2022 ($-1,868.57 Mil) to Dec. 2023 ($-1,964.47 Mil).

Precigen Retained Earnings Historical Data

The historical data trend for Precigen's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Precigen Retained Earnings Chart

Precigen Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Retained Earnings

Get a 7-Day Free Trial

-1,652.87

-1,823.39

-1,915.56

-1,868.57

-1,964.47

Precigen Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Retained Earnings	Get a 7-Day Free Trial															-1,868.57	-1,891.30	-1,911.62	-1,931.42	-1,964.47

Precigen Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Precigen (NAS:PGEN) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.

Precigen (Precigen) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Precigen Inc (NAS:PGEN) » Definitions » Retained Earnings

Comparable Companies

Traded in Other Exchanges

I5X:Germany I5X:Germany

Address

20374 Seneca Meadows Parkway, Germantown, MD, USA, 20876

Website

http://www.precigen.com

Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.

Executives

Jeffrey B Kindler	director	35 E. 62ND ST, NEW YORK NY 10065
Randal J Kirk	director, 10 percent owner, officer: Chief Executive Officer	1881 GROVE AVENUE, RADFORD VA 24141
Dean J Mitchell	director	C/O BRISTOL MYERS SQUIBB CO, 345 PARK AVE, NEW YORK NY 10164
Helen Sabzevari	director, officer: President and CEO	20374 SENECA MEADOWS PARKWAY, GERMANTOWN MD 20876
Rutul R Shah	officer: Chief Operating Officer	C/O PRECIGEN, INC., 20374 SENECA MEADOWS PARKWAY, GERMANTOWN MD 20876
Harry Jr. Thomasian	officer: Chief Financial Officer	C/O PRECIGEN, INC., 20374 SENECA MEADOWS PARKWAY, GERMANTOWN, MD 20876
Jeffrey Thomas Perez	officer: SVP, IP Affairs	20358 SENECA MEADOWS PARKWAY, GERMANTOWN MD 20876
Donald P. Lehr	officer: Chief Legal Officer	20374 SENECA MEADOWS PARKWAY, GERMANTOWN MD 20876
Fred Hassan	director	C/O CARET GROUP,, 1100 HOLLAND DR., BOCA RATON FL 33487
Steven Frank	director	20374 SENECA MEADOWS PARKWAY, GERMANTOWN MD 20876
Vinita D Gupta	director	20374 SENECA MEADOWS PARKWAY, GERMANTOWN MD 20876
Robert B Shapiro	director	155 WEST BURTON PLACE, #2, CHICAGO IL 60610
Cesar L Alvarez	director	C/O PEDIATRIX MEDICAL GROUP, LEGAL DEPT 1301- CONCORD TERRACE, SUNRISE FL 33323
James S Turley	director	9 MUIRFIELD LANE, SAINT LOUIS MO 63141
Ares Trading S.a.	10 percent owner	ZONE INDUSTRIELLE DE L'OURIETTAZ, AUBONNE V8 1170